These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 2151441)
1. Comparison of the target sites and mechanisms of action of glycopeptide and lipoglycodepsipeptide antibiotics. Reynolds PE; Somner EA Drugs Exp Clin Res; 1990; 16(8):385-9. PubMed ID: 2151441 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of peptidoglycan biosynthesis by ramoplanin. Somner EA; Reynolds PE Antimicrob Agents Chemother; 1990 Mar; 34(3):413-9. PubMed ID: 2334153 [TBL] [Abstract][Full Text] [Related]
3. Complexation of peptidoglycan intermediates by the lipoglycodepsipeptide antibiotic ramoplanin: minimal structural requirements for intermolecular complexation and fibril formation. Cudic P; Kranz JK; Behenna DC; Kruger RG; Tadesse H; Wand AJ; Veklich YI; Weisel JW; McCafferty DG Proc Natl Acad Sci U S A; 2002 May; 99(11):7384-9. PubMed ID: 12032292 [TBL] [Abstract][Full Text] [Related]
4. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Reynolds PE Eur J Clin Microbiol Infect Dis; 1989 Nov; 8(11):943-50. PubMed ID: 2532132 [TBL] [Abstract][Full Text] [Related]
5. Extraction and Analysis of Peptidoglycan Cell Wall Precursors. Binda E; Carrano L; Marcone GL; Marinelli F Methods Mol Biol; 2016; 1440():153-70. PubMed ID: 27311671 [TBL] [Abstract][Full Text] [Related]
6. Mechanisms and implications of glycopeptide resistance in enterococci. Derlot E; Courvalin P Am J Med; 1991 Sep; 91(3B):82S-85S. PubMed ID: 1656750 [TBL] [Abstract][Full Text] [Related]
7. The lantibiotic mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation. Brötz H; Bierbaum G; Reynolds PE; Sahl HG Eur J Biochem; 1997 May; 246(1):193-9. PubMed ID: 9210483 [TBL] [Abstract][Full Text] [Related]
8. The mechanism of action of ramoplanin and enduracidin. Fang X; Tiyanont K; Zhang Y; Wanner J; Boger D; Walker S Mol Biosyst; 2006 Jan; 2(1):69-76. PubMed ID: 16880924 [TBL] [Abstract][Full Text] [Related]
9. Presence of UDP-N-acetylmuramyl-hexapeptides and -heptapeptides in enterococci and staphylococci after treatment with ramoplanin, tunicamycin, or vancomycin. Billot-Klein D; Shlaes D; Bryant D; Bell D; Legrand R; Gutmann L; van Heijenoort J J Bacteriol; 1997 Aug; 179(15):4684-8. PubMed ID: 9244253 [TBL] [Abstract][Full Text] [Related]
11. Chemistry and biology of the ramoplanin family of peptide antibiotics. McCafferty DG; Cudic P; Frankel BA; Barkallah S; Kruger RG; Li W Biopolymers; 2002; 66(4):261-84. PubMed ID: 12491539 [TBL] [Abstract][Full Text] [Related]
12. On the mechanism of action of vancomycin: inhibition of peptidoglycan synthesis in Gaffkya homari. Hammes WP; Neuhaus FC Antimicrob Agents Chemother; 1974 Dec; 6(6):722-8. PubMed ID: 4451345 [TBL] [Abstract][Full Text] [Related]
13. New insights into glycopeptide antibiotic binding to cell wall precursors using SPR and NMR spectroscopy. Treviño J; Bayón C; Ardá A; Marinelli F; Gandolfi R; Molinari F; Jimenez-Barbero J; Hernáiz MJ Chemistry; 2014 Jun; 20(24):7363-72. PubMed ID: 24805824 [TBL] [Abstract][Full Text] [Related]
14. Molecular modeling of Gram-positive bacteria peptidoglycan layer, selected glycopeptide antibiotics and vancomycin derivatives modified with sugar moieties. Ślusarz R; Szulc M; Madaj J Carbohydr Res; 2014 May; 389():154-64. PubMed ID: 24685455 [TBL] [Abstract][Full Text] [Related]
15. Rethinking ramoplanin: the role of substrate binding in inhibition of peptidoglycan biosynthesis. Helm JS; Chen L; Walker S J Am Chem Soc; 2002 Nov; 124(47):13970-1. PubMed ID: 12440876 [TBL] [Abstract][Full Text] [Related]
16. Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics. Printsevskaya SS; Pavlov AY; Olsufyeva EN; Mirchink EP; Preobrazhenskaya MN J Med Chem; 2003 Mar; 46(7):1204-9. PubMed ID: 12646030 [TBL] [Abstract][Full Text] [Related]
17. In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile. Biavasco F; Manso E; Varaldo PE Antimicrob Agents Chemother; 1991 Jan; 35(1):195-7. PubMed ID: 1826593 [TBL] [Abstract][Full Text] [Related]
18. Modification of peptidoglycan precursors is a common feature of the low-level vancomycin-resistant VANB-type Enterococcus D366 and of the naturally glycopeptide-resistant species Lactobacillus casei, Pediococcus pentosaceus, Leuconostoc mesenteroides, and Enterococcus gallinarum. Billot-Klein D; Gutmann L; Sablé S; Guittet E; van Heijenoort J J Bacteriol; 1994 Apr; 176(8):2398-405. PubMed ID: 8157610 [TBL] [Abstract][Full Text] [Related]
19. Resistance to glycopeptide antibiotics in the teicoplanin producer is mediated by van gene homologue expression directing the synthesis of a modified cell wall peptidoglycan. Beltrametti F; Consolandi A; Carrano L; Bagatin F; Rossi R; Leoni L; Zennaro E; Selva E; Marinelli F Antimicrob Agents Chemother; 2007 Apr; 51(4):1135-41. PubMed ID: 17220405 [TBL] [Abstract][Full Text] [Related]
20. Glycopeptide antibiotics and their novel semi-synthetic derivatives. Jeya M; Moon HJ; Lee KM; Kim IW; Lee JK Curr Pharm Biotechnol; 2011 Aug; 12(8):1194-204. PubMed ID: 21470154 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]